A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 701–800 of 1,000
Emerging Strategies for Targeting Cell Adhesion in Multiple Myeloma
Nair, R. R., Gebhard, A. W., Emmons, M. F., & Hazlehurst, L. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00006-3 · Cited by 12
on behalf of the Heinz Nixdorf Recall Study Investigative Group, Pelzer, B. W., Arendt, M., Moebus, S., Eisele, L., Jöckel, K., Dührsen, U., & Dürig, J. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3305-x · Cited by 12
“By comparison, disappearance of the M-protein has been observed in only 2–5% of patients with conventional MGUS [3, 11, 12].”
Sethi, S. M., Nast, C. C., D’Agati, V. D., Fervenza, F. C., Glassock, R. J., Stokes, M. B., Vriese, A. S. D., Appel, G. B., Chang, A., Cosio, F. G., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.025 · Cited by 12
“The patient has a detectable serum/urine MIg, but no renal disease associated with MIg is identifiable: In such cases (1) or (2) is recommended and should be highlighted in the report:”
BackgroundSandecká, V., Adam, Z., Krejčí, M., Štork, M., Rehak, Z., Koukalová, R., Sevcikova, S., Brožová, L., Král, Z., Mayer, J., et al. (2020) · Neoplasma · doi:10.4149/neo_2020_191104n1137 · Cited by 12
“MGUS is a known precursor of more serious diseases, such as MM, MW, and primary amyloidosis, but most patients with MGUS do not develop a plasma cell malignancy [7].”
BackgroundClinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK
Agbuduwe, C., Yang, H., Gaglani, J., & Ajithkumar, T. (2020) · Clinical Medicine · doi:10.7861/clinmed.2019-0488 · Cited by 12
Alcohol and tobacco use and risk of multiple myeloma: A case‐control study
Cheah, S., Bassett, J. K., Bruinsma, F., Cozen, W., Hopper, J. L., Jayasekara, H., Joshua, D., MacInnis, R. J., Prince, H. M., Vajdic, C. M., et al. (2021) · eJHaem · doi:10.1002/jha2.337 · Cited by 12
“MM is typically preceded by the asymptomatic precursor condition monoclonal gammopathy of undetermined significance (MGUS), which progresses to multiple myeloma at an average rate of 1% per year [2].”
BackgroundEmerging role of exosomes in hematological malignancies
Pandian, S. R. K., Vijayakumar, K. K., Kunjiappan, S., Babkiewicz, E., & Maszczyk, P. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00850-z · Cited by 12
“MM accounts for around 10% of the hematological malignancies [100], for which African Americans are highly vulnerable [101].”
BackgroundPathologic Mandibular Fracture as the Presenting Manifestation of Multiple Myeloma
Boffano, P., Viterbo, S., Barreca, A., & Berrone, S. (2011) · Journal of Craniofacial Surgery · doi:10.1097/scs.0b013e31821c6cbe · Cited by 13
“Monoclonal gammopathy of undetermined clinical significance seems to progress to smoldering MM and finally to symptomatic intramedullary and extramedullary MM or plasma cell leukemia.(9,10) As various authors affirm, few differences can be found between monoclonal gammopathy of undetermined significance and MM.”
BackgroundHashimoto, T., Arakawa, K., Ohta, Y., Suehiro, T., Uesugi, N., Nakayama, M., & Tsuchihashi, T. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.1882 · Cited by 12
“Bone marrow plasma cell percentage of 6%-9% carries twice the risk of progression compared to those with 5% or less (21, 22).”
BackgroundFactors affecting outcome of patients with multiple myeloma.
Basit, A., Siddiqui, N., Hameed, A., Muzaffar, N., & Athar, S. (2014) · PubMed · Cited by 14
Monoclonal Gammopathy of Undetermined Significance: An Update for Nephrologists
Parry, H., Pratt, G., & Hutchison, C. A. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.07.006 · Cited by 13
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A. G., Harrison, S. J., Mollee, P. N., Roberts, A. W., Horvath, N., Talaulikar, D., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12688 · Cited by 13
Renal involvement in non-malignant IgM gammopathy
Ramos, R., Poveda, R., Sarrá, J., Domingo, A., Carreras, L., & Grinyo, J. M. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl709 · Cited by 12
“Nevertheless, light chain deposition renal disease has also been described in non-malignant monoclonal gammopathy, namely in IgG or IgA plasma cell dyscrasia [2,3].”
BackgroundOverview of monoclonal gammopathies of undetermined significance
Vogt, R. F., & Marti, G. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06860.x · Cited by 12
“However, some overlap in these outcomes is evident from the extensive studies of MGUS (Kyle, 1978, 1993; Kyle et al, 2002, 2004, 2006) and the much more limited studies of MBL. MGUS can occasionally progress to CLL or non-Hodgkin lymphoma (NHL), and at least one report describes a case of MBL that…”
Stergiou, I. Ε., Tsironis, C., Papadakos, S. P., Tsitsilonis, O., Dimopoulos, M. A., & Theocharis, S. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042369 · Cited by 11
Li, H., Lu, W., Jin, Q., Sun, J., Gao, L., Hu, J., Ling, Y., Zhao, W., Zhang, Y., & Xie, X. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00253 · Cited by 12
Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Murakami, N., Blosser, C. D., Webber, A. B., Gupta, G., Singh, N., Boppana, S., Master, S. R., Parasuraman, R. K., Campagnaro, E. L., Java, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.07.011 · Cited by 11
Terpos, E., Tasidou, A., Eleftherakis-Papaiakovou, E., Christoulas, D., Gavriatopoulou, M., Gkotzamanidou, M. A., Ρούσσου, Μ., Kastritis, E., Papadaki, T., & Dimopoulos, M. A. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2011.n.024 · Cited by 11
Sixty as the new forty: considerations on older related stem cell donors
Anderlini, P. N. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.201 · Cited by 12
Zeig‐Owens, R., Goldfarb, D. G., Luft, B. J., Yang, X., Murata, K., Ramanathan, L. V., Thoren, K. L., Doddi, S., Shah, U. A., Mueller, A. K., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00709-2 · Cited by 12
Mortality in the US Populations With Monoclonal Gammopathy of Undetermined Significance
Ji, M., Huber, J. H., Schoen, M. W., Sanfilippo, K. M., Colditz, G. A., Wang, S., & Chang, S. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2278 · Cited by 11
Heritability of Hematologic Malignancies: From Pedigrees to Genomics
Churpek, J. E., & Onel, K. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.06.001 · Cited by 11
“MGUS, a precursor condition to MM, has been identified in 3% to 6% of healthy adults more than 50 years of age (reviewed in Ref.94) and is associated with a 1% to 3% per year risk of progressing to overt MM.95 Both MM and MGUS are twice as common in African Americans compared with whites and are less common in Asians.”
BackgroundInfluentialImmune Response to Premalignancy: Insights from Patients with Monoclonal Gammopathy
Dhodapkar, M. V. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1358.004 · Cited by 11
Goebel, T. E., Schiltz, N. K., Woodside, K. J., Pillai, A. C., Caimi, P. F., Lazarus, H. M., Koroukian, S. M., & Campagnaro, E. L. (2015) · Clinical Transplantation · doi:10.1111/ctr.12595 · Cited by 11
Babarović, E., Valković, T., Budisavljević, I., Balen, I., Štifter, S., Duletić‐Načinović, A., Lučin, K., & Jonjić, N. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.11.021 · Cited by 11
Fukui, T., Tanimura, Y., Matsumoto, Y., Horitani, S., Tomiyama, T., & Okazaki, K. (2018) · Case Reports in Gastroenterology · doi:10.1159/000494919 · Cited by 11
Monoclonal Gammopathies of ‘Neurological Significance’: Paraproteinemic Neuropathies
Mani, A. M., Devasia, A. J., Nair, A. V., Benjamin, R. N., Prabhakar, A. T., Sivadasan, A., Mathew, V., Aaron, S., George, B., & Alexander, M. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2020.278 · Cited by 11
“Studies have shown that paraproteins are present in 3% to 4% of the population older than the age of 50 years, more than 5% of the population older than the age of 70 years, and can be detected in approximately 3% to 5% of patients with chronic peripheral neuropathy.(2,3) Approximately half of them are causally relate…”
BackgroundLamb, M. J. E., Smith, A. G., Painter, D., Kane, E. V., Bagguley, T., Newton, R., Howell, D. A., Cook, G., Tute, R. M. D., Rawstron, A. C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-041296 · Cited by 11
The Spectrum of Ocular Manifestations in Patients with Waldenström’s Macroglobulinemia
Dammacco, R., Lisch, W., Kivelä, T., Terpos, E., Kastritis, E., Sisto, D., Mavilio, A., Ria, R., Alessio, G., Vacca, A., et al. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1933068 · Cited by 11
“5% per year.(6) Recently, the international prognostic scoring system(7) was updated to allow a more precise risk assessment of WM patients.”
BackgroundThe Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
Jasiński, M., Biliński, J., & Basak, G. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741376 · Cited by 11
“Only rarely does it progress to symptomatic MM (1% of patients/year) (3), which can be associated with symptoms that manifest as a result of hypercalcaemia, renal failure, anaemia, and bone lesions.”
BackgroundPierro, A., Posa, A., Astore, C., Sciandra, M., Tanzilli, A., Petrosino, A., del Balso, M. S., Fraticelli, V. L., Cilla, S., & Iezzi, R. (2021) · Life · doi:10.3390/life11121320 · Cited by 11
Kortüm, K. M., Engelhardt, M. M., Rasche, L., Knop, S. T., & Einsele, H. (2013) · Der Internist · doi:10.1007/s00108-013-3336-2 · Cited by 12
Myelomagenesis: Capturing Early Microenvironment Changes
Korde, N., & Marić, I. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.004 · Cited by 14
Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenström Macroglobulinemia
Kristinsson, S. Y., Björkholm, M., & Landgren, O. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.02.010 · Cited by 11
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment
Kapoor, P., Ansell, S. M., & Braggio, E. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_16 · Cited by 11
Monoclonal gammopathy of undetermined significance as viewed by haematology healthcare professionals
McShane, C. M., Murphy, B., Lim, K. H., & Anderson, L. A. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12962 · Cited by 11
Tavee, J. O. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000523 · Cited by 11
Go, R. S., Heien, H. C., Sangaralingham, L. R., Habermann, E. B., & Shah, N. D. (2017) · Haematologica · doi:10.3324/haematol.2017.179978 · Cited by 11
“3/100 person-years, respectively.(2,3) These studies included patients ≥50 years residing in southeastern Minnesota who were part of epidemiological surveys in which serological screening for monoclonal protein was performed.”
BackgroundResultBaldursdóttir, T. R., Löve, Þ. J., Gíslason, G. K., Björkholm, M., Mellqvist, U., Lund, S. H., Blimark, C. H., Turesson, I., Hultcrantz, M. L., Landgren, O., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13563 · Cited by 12
Jønsson, V., Tjønnfjord, G. E., Samuelsen, S. O., Johannesen, T. B., Olsen, J. H., Sellick, G. S., Houlston, R. S., Yuille, M., & Catovsky, D. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701686273 · Cited by 11
“Moreover we have not surveyed for low-grade disease in the form of clonal lymphocytosis of unknown significance (CLUS) [24], monoclonal gammopathy of unknown significance (MGUS) [25] and early maltomas [26], Pedigree 1.”
BackgroundConventional therapy and approach to management
Rajkumar, S. V., & Kyle, R. A. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.011 · Cited by 13
Self-citationGenomics in Multiple Myeloma: Biology and Clinical Implications
Chng, W. J., & Fonseca, R. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.6.563 · Cited by 11
“0%, depending on the initial level of monoclonal immunoglobulin [15].”
BackgroundMONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING MULTIPLE MYELOMA
Kyle, R. A., & Rajkumar, S. V. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511551901.013 · Cited by 11
Self-citationBueno, C., Lopes, L. F., & Menéndez, P. R. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.06.001 · Cited by 11
Gobel, B. H. (2004) · Clinical journal of oncology nursing · doi:10.1188/04.cjon.316-320 · Cited by 11
Maeng, C. V., Rögnvaldsson, S., Long, T. E., Brieghel, C., Hermansen, E., Niemann, C. U., Grønbæk, K., Kristinsson, S. Y., & Þorsteinsdóttir, S. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01289-7 · Cited by 12
Asymptomatic Monoclonal Gammopathies
Bories, C., & Jagannath, S. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.05.004 · Cited by 10
Current Understanding of Systemic Amyloidosis and Underlying Disease Mechanisms
Picken, M. M. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.10.057 · Cited by 10
Suivi évolutif des gammapathies monoclonales de signification indéterminée
Decaux, O., Marc Cuggia, A., Ruelland, A., Cazalets, C., Cador, B., Jégo, P., & Grosbois, B. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74771-6 · Cited by 10
Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis
Xu, W. L., Li, J., Wu, Y., Cao, X., Fan, L., Qiao, C., Liu, Q., Yao, L., & Miao, K. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.029 · Cited by 10
Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future
Landgren, O., & Rajkumar, S. V. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.009 · Cited by 10
Self-citationThomas, C. L., Ffolkes, L., & Akhras, V. (2015) · Clinical and Experimental Dermatology · doi:10.1111/ced.12622 · Cited by 10
Samaras, P., Bargetzi, M. J., Betticher, D. C., Duchosal, M. A., Heim, D. A., Hess, U., Ketterer, N., Lerch, E., Matthes, T., Mey, U., et al. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14100 · Cited by 11
Concomitant MDS with isolated 5q deletion and MGUS : case report and review of molecular aspects
Nolte, F., Mossner, M., Jann, J.-C., Nowak, D., Boch, T., Müller, N., Hofmann, W., & Metzgeroth, G. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12827 · Cited by 11
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance
Sandecká, V., Hájek, R., Pour, L., Špıčka, I., Ščudla, V., Gregora, E., Radocha, J., Walterová, L., Kessler, P., Zahradová, L., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12894 · Cited by 10
Clonal haematopoiesis of emerging significance
Hammond, D. E., & Loghavi, S. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.005 · Cited by 11
Kim, M., Jeon, K., Hutt, K. R., Zlotnicki, A. M., Kim, H. J., Lee, J., Kim, H.-S., Kang, H. J., & Lee, Y. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253541 · Cited by 10
van de Mortel, J. P. M., D’Sa, S., Vrancken, A. F. J. E., Notermans, N. C., Vos, J. M. I., & Minnema, M. C. (2022) · Hemato · doi:10.3390/hemato3040045 · Cited by 10
Ghansah, H., Debreceni, I. B., Váróczy, L., Rejtő, L., Lóczi, L., Bagoly, Z., & Kappelmayer, J. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.01.010 · Cited by 10
Emery, A., Moore, S. E., Crowe, J., Murray, J., Peacock, O., Thompson, D., Betts, F., Rapps, S., Ross, L., Rothschild-Rodriguez, D., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11817-6 · Cited by 10
“The overall risk of disease progression to MM ranges from 1 to 10% per year for MGUS and SMM, respectively [5, 6].”
BackgroundCancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape
Bhatia, A., & Kumar, Y. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_12 · Cited by 10
Ruiz‐Delgado, G. J., & Rangel, J. D. G. (2004) · PubMed · Cited by 10
Transient Monoclonal Gammopathy Induced by DisseminatedStaphylococcus aureusInfection
Stoimenis, D., Spyridonidou, C., & Papaioannou, N. (2012) · Case Reports in Medicine · doi:10.1155/2012/607104 · Cited by 10
“Most of the times the presence of a paraprotein in the serum implies a plasma cell dyscrasia such as multiple myeloma, Waldenström’s macroglobulinemia, cryoglobulinemia, and primary amyloidosis or it may derives from abnormal B cells that have not been differentiated in plasma cells just like in leukemias or lymphomas…”
Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma
Olteanu, H. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.09.009 · Cited by 11
Neurological complications in plasma cell dyscrasias
Bayat, E., & Kelly, J. J. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53502-3.00020-3 · Cited by 10
Orban, E., Arendt, M., Hennig, F., Lucht, S. A., Eisele, L., Jakobs, H. J., Dürig, J., Hoffmann, B. H., Jöckel, K., & Moebus, S. (2017) · Environment International · doi:10.1016/j.envint.2017.08.007 · Cited by 10
Flow cytometric aberrancies in plasma cell myeloma and MGUS – correlation with laboratory parameters
Gupta, S., Karandikar, N. J., Ginader, T., Bellizzi, A. M., & Holman, C. (2018) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21624 · Cited by 13
Plasma cell diseases and organ transplant: A comprehensive review
Cowan, A. J., Johnson, C. K., & Libby, E. N. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14731 · Cited by 10
Gran, C., Liwing, J., Wagner, A. K., Verhoek, A., Gezin, A., Alici, E., & Nahi, H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25999 · Cited by 10
Murphy, B., McShane, C. M., Santin, O., Treanor, C., Byrne, B., Donnelly, M., & Anderson, L. A. (2021) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2021.101901 · Cited by 10
Analytical variation in the measurement of serum monoclonal component by capillary electrophoresis
Luraschi, P., Infusino, I., Merlotti, C., & Franzini, C. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.06.016 · Cited by 10
Are all myelomas preceded by MGUS?
Bladé, J., Rosiñol, L., & Cibeira, M. T. (2009) · Blood · doi:10.1182/blood-2009-03-207241 · Cited by 12
Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis
Garton, M. J., Keir, G., Dickie, A., Steven, M. M., & Rennie, J. A. N. (2006) · Rheumatology · doi:10.1093/rheumatology/kei246 · Cited by 10
Kyle, R. A., & Dispenzieri, A. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00094-5 · Cited by 10
Self-citationMyeloma and Macroglobulinemia: What Are the Criteria for Diagnosis?
Stone, M. J. (2002) · Clinical Lymphoma · doi:10.3816/calm2002.n.007 · Cited by 10
miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance
Pirzaman, A. T., Ebrahimi, P., Hasanpour, A., Shakeri, M., Babajani, B., Ganji, Z. P., Babaei, H., Rahmati, A., Hosseinzadeh, R., Doostmohamadian, S., et al. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231202391 · Cited by 12
Verma, K. P., Steuer, R. Z., & Edwards, C. V. (2023) · Hemato · doi:10.3390/hemato4040027 · Cited by 11
Kul, A. N., & Kurt, B. O. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14030221 · Cited by 9
“More than 50% of individuals diagnosed with MGUS have had the condition for more than 10 years prior to multiple myeloma diagnosis [45,46].”
BackgroundDNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma
Neeli, P. K., Maza, P. A. M., Chai, D., Zhao, D., Hoi, X. P., Chan, K. S., Young, K. H., & Li, Y. (2024) · npj Vaccines · doi:10.1038/s41541-024-00979-w · Cited by 9
Karathanasis, N., & Spyrou, G. M. (2025) · Cancers · doi:10.3390/cancers17020332 · Cited by 10
“MGUS transitions to multiple myeloma or related malignancies at a rate of 1% per year [13,14].”
Primary immune deficiencies: practical questions
Gouilleux‐Gruart, V., SCHLEINITZ, N., & Fischer, A. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/01.all.0000433133.93564.c7 · Cited by 10
99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS
Giovanella, L., Taborelli, M., Ceriani, L., Zucca, E., Cavalli, F., & Delaloye, A. B. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3282f5e5df · Cited by 9
Kyrtsonis, M. C., Bartzis, V., Papanikolaou, X., Koulieris, E., Georgiou, G., Dimou, M., Tzenou, T., & Panayiotidis, P. (2010) · The Application of Clinical Genetics · doi:10.2147/tacg.s7456 · Cited by 14
McShane, C. M., Murray, L., Engels, E. A., & Anderson, L. A. (2013) · British Journal of Haematology · doi:10.1111/bjh.12671 · Cited by 9
“IgM monoclonal gammopathy of undetermined significance (MGUS) carries a 1–1 5% annual risk of progression to LPL/WM (Kyle et al, 2002).”
BackgroundTherapeutic Options in the Management of Myeloma Bone Disease
Berenson, J. R. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.06.009 · Cited by 10
Evaluation of competing risks prediction models using polytomous discrimination index
Ding, M., Ning, J., & Li, R. (2020) · Canadian Journal of Statistics · doi:10.1002/cjs.11583 · Cited by 9
“For example, in a study of monoclonal gammopathy of undetermined significance (MGUS), patients may experience progression to a plasma cell malignancy (PCM) or die without experiencing PCM. Development of PCM and death without PCM represent different courses of disease progression and form a competing risks structure.”
BackgroundMethodInfluentialRögnvaldsson, S., Aspelund, T., Þorsteinsdóttir, S., Turesson, I., Björkholm, M., Landgren, O., & Kristinsson, S. Y. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13633 · Cited by 9
Kang, K., Song, J. E., Lee, B., Jeon, M. J., Yu, E. S., Kim, D. S., Lee, S. R., Sung, H. J., Choi, C. W., Park, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97664-y · Cited by 11
Characterizing the mutational landscape of MM and its precursor MGUS.
Farswan, A., Gupta, A., Jena, L., Ruhela, V., Kaur, G., & Gupta, R. (2022) · PubMed · Cited by 9
McMaster, M. L., & Csákó, G. (2007) · International Journal of Cancer · doi:10.1002/ijc.23229 · Cited by 9
Saraf, S. L., Patel, P. R., & Rondelli, D. (1970) · Journal of Advances in Internal Medicine · doi:10.3126/jaim.v1i1.5837 · Cited by 10
“The standard-risk category included MM patients with hyperdiploidy, t(11;14), or t(6;14).”
BackgroundGwathmey, T. M., Willis, M. S., Tatreau, J. R., Wang, S., & McCudden, C. R. (2015) · PubMed Central · Cited by 9
Strategy for Detecting and Following Monoclonal Gammopathies
Katzmann, J. A., & Keren, D. F. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch11 · Cited by 9
Campbell, J. P., Heaney, J. L. J., Pandya, S., Afzal, Z., Kaiser, M., Owen, R. G., Child, J. A., Cairns, D. A., Gregory, W. M., Morgan, G. J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30209-0 · Cited by 10
“with age and is 3-4% in adults over 50 years old in the general population (4-7), is more common in men and twice as common in blacks as whites (7, 8), and progresses to MM at a rate of 0·5 - 1% each year (9, 10).”
BackgroundLehners, N., Ellert, E., Xu, J., Hillengaß, J., Leichsenring, J., Stenzinger, A., Goldschmidt, H., Andrulis, M., & Raab, M. S. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1443450 · Cited by 9
“SMM is an intermediate stage between MGUS and symptomatic MM and differs from MGUS in having a higher tumor mass and is associated with a considerably higher rate of progression to symptomatic MM [1,2,4].”
BackgroundAilawadhi, S., Dholaria, B., Khurana, S., Sher, T., Alegria, V. R., Paulus, A., Ailawadhi, M., Mehta, A., Chanan-Khan, A. A., & Roy, V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15458 · Cited by 9
Vlummens, P., Veirman, K. D., Menu, E., Bruyne, E. D., Offner, F. C., Vanderkerken, K., & Maes, K. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00740 · Cited by 9
“Symptomatic MM disease is typically preceded by a precursor state termed monoclonal gammopathy of undetermined significance (MGUS) (Kyle et al., 2002).”
BackgroundInfluentialThe Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients
Gagnon, M.-F., Cardinal, H., Émond, J.-P., Latour, M., & Lemieux, B. (2019) · Transplantation Direct · doi:10.1097/txd.0000000000000937 · Cited by 10
Pulmonale und pleurale Manifestationen beim Plasmozytom
Schelle, M., Schreiber, C., Knolle, J., Florschütz, A., Kachel, R., & Schreiber, J. (2006) · Pneumologie · doi:10.1055/s-2006-944275 · Cited by 9
Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia
Miura, K., Lida, S., Hanamura, I., Kato, M., Banno, S., Ishida, T., Kusumoto, S., Takeuchi, G., Miwa, H., Nitta, M., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01445.x · Cited by 10
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.